SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Muehler Andreas

(Last)

(First)

(Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK

10036

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/10/2021

3. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	284,480	I	See footnote⁽¹⁾
Common Stock	10,006	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option	⁽²⁾	03/01/2031	Common Stock	65,000	$15.72	D
Stock Option	⁽³⁾	07/01/2030	Common Stock	44,000	$12.3	D
Stock Option	⁽⁴⁾	08/12/2029	Common Stock	10,000	$13.34	D
Stock Option	⁽⁵⁾	08/01/2029	Common Stock	30,000	$13.29	D

Explanation of Responses:

1. The Reporting Person is Director of Xanomed GmbH, which is the record holder of 284,480 shares of common stock of the Issuer, and exercises voting and dispositive power over such shares.

2. 16,250 of the shares underlying the option vest on the first anniversary of the grant date. Thereafter, 1,360 of the underlying shares vest on the thirteen month anniversary of the grant date and 1,354 of the underlying shares vest on each successive one-month anniversary thereafter for the next 35 months.

3. 11,000 of the shares underlying the option vest on the first anniversary of the grant date. Thereafter, 940 of the underlying shares vest on the thirteen month anniversary of the grant date and 916 of the underlying shares vest on each successive one-month anniversary thereafter for the next 35 months.

4. 2,500 of the shares underlying the option vest on the first anniversary of the grant date. Thereafter, 220 of the underlying shares vest on the thirteen month anniversary of the grant date and 208 of the underlying shares vest on each successive one-month anniversary thereafter for the next 35 months.

5. 7,500 of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.

	/s/ Andreas Muehler	03/15/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.